Skip to main content

Breadcrumb

  1. Home

Dual approach using proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Dual approach using proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients

Custom PhenoImager™ fluorescent multiplex IHC panel identifies mature tertiary lymphoid structures in colorectal cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Custom PhenoImager™ fluorescent multiplex IHC panel identifies mature tertiary lymphoid structures in colorectal cancer

Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP)

Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients

Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 70
  • Page 71
  • Page 72
  • Page 73
  • Page 74
  • Page 75
  • Page 76
  • Page 77
  • Page 78
  • …
  • Next page Next
  • Last page Last
Subscribe to